The U.S. Food and Drug Administration (FDA) has approved FoundationOne Liquid CDx, a blood test that can be used to identify cancer patients who may benefit from certain targeted therapies, including the FDA-approved prostate cancer therapy Rubraca (rucaparib). The test became commercially available on Aug. 28, and is covered by Medicare and Medicare Advantage for qualifying individuals across all solid tumors. “We believe that cancer patients and their physicians deserve the highest quality genomic testing to make…
You must be logged in to read/download the full post.
The post FDA Approves Blood Test That Can Identify Cancers Eligible for Targeted Therapies appeared first on BioNewsFeeds.